In short
CDR132L Sodium is currently being studied in clinical trials for patients who have experienced a heart attack (myocardial infarction) and are left with reduced heart function. This innovative drug is being tested to see if it can improve heart function and overall well-being in these patients. The trial aims to assess the safety and effectiveness of CDR132L Sodium when given in addition to standard care treatments.
At a glance
- Drug Name
- CDR132L Sodium
- Trial Phase
- Phase 2
- Condition Studied
- Reduced heart function (LVEF ≤ 45%) after myocardial infarction
- Administration
- Intravenous infusion, 3 doses given 28 days apart
- Dosages Tested
- 5 mg/kg and 10 mg/kg
- Primary Endpoint
- Change in Left Ventricular End-Systolic Volume Index (LVESVI) at 6 months
- Key Secondary Endpoints
- Safety, changes in heart function, biomarkers, patient well-being, heart failure episodes
- Study Duration
- 12 months follow-up
- Number of Participants
- Approximately 280 (90 per group)
What is CDR132L SODIUM?
CDR132L SODIUM is an innovative medication currently being studied for its potential to help patients with heart problems after a heart attack. It's a type of drug known as a "locked ASO" (antisense oligonucleotide), which is a specially designed molecule that can influence how genes work in the body. This medication is given as an intravenous infusion, which means it's delivered directly into the bloodstream through a vein.
Medical Conditions Targeted
CDR132L SODIUM is being investigated to treat several related heart conditions:
- Acute Myocardial Infarction: This is the medical term for a heart attack, where blood flow to part of the heart is blocked, causing damage to the heart muscle.
- Left-Sided Heart Failure: A condition where the left side of the heart can't pump blood effectively to the rest of the body.
- Heart Failure with Reduced Ejection Fraction: This occurs when the heart muscle doesn't squeeze forcefully enough, and less blood is pumped out to the body with each heartbeat.
The study focuses on patients who have experienced a heart attack and now have a reduced left ventricular ejection fraction (LVEF) of 45% or less. LVEF is a measure of how well the heart is pumping blood, and a normal LVEF is typically between 50% and 70%.
How CDR132L SODIUM Works
While the exact mechanism isn't fully explained in the trial information, CDR132L SODIUM is designed to target a specific microRNA called miR-132. MicroRNAs are small molecules that help regulate gene expression. By targeting miR-132, CDR132L SODIUM may help improve heart function and reduce the progression of heart failure after a heart attack.
Current Clinical Trial
CDR132L SODIUM is currently being studied in a Phase 2 clinical trial called HF-REVERT. This trial aims to:
- Assess how well CDR132L SODIUM works compared to a placebo (a treatment with no active ingredients).
- Determine the safety of different doses of the medication.
- Evaluate its effects on heart function, biomarkers (substances in the blood that can indicate heart health), and patient well-being.
- Investigate how it affects the frequency of heart failure episodes.
Dosage and Administration
In the clinical trial, CDR132L SODIUM is being tested at two different dose levels:
- 5 mg/kg (milligrams per kilogram of body weight)
- 10 mg/kg
The medication is given as three separate intravenous infusions, each 28 days apart. This means patients receive the treatment on day 1, day 29, and day 57 of the study.
Potential Benefits
While the full benefits of CDR132L SODIUM are still being studied, researchers hope it may:
- Improve heart function after a heart attack
- Reduce the progression of heart failure
- Enhance patients' quality of life
- Decrease the number of hospitalizations due to heart failure
Who Might Be Eligible for Treatment?
The current clinical trial has specific criteria for who can participate. Some key factors include:
- Adults aged 30 to 80 years
- Recent heart attack (within 14 days)
- Reduced heart function (LVEF ≤ 45%)
- Body weight of 120 kg or less
- Elevated levels of a substance called NT-proBNP in the blood, which can indicate heart stress
It's important to note that these criteria are for the clinical trial and may not reflect future eligibility if the treatment becomes widely available.
Safety Considerations
As with any new medication, safety is a crucial concern. The clinical trial excludes people with certain conditions to minimize risks. Some of these include:
- Bleeding disorders or low platelet counts
- Poorly controlled diabetes
- Certain heart rhythm abnormalities
- Severe heart failure (New York Heart Association class IV)
- Severe kidney or liver problems
The trial will closely monitor participants for any side effects or safety concerns throughout the study period.